Available Vaccines
Chickenpox (Varicella)
Introduction
Chickenpox is caused by the varicella-zoster virus (VZV), now classified as Varicellavirus humanalpha3. It is a double-stranded virus that belongs to the Varicellovirus genus and Orthoherpesviridae family. It is transmitted by the airborne route or direct contact with fluid from vesicles. VZV is highly contagious with 61–100% of household contacts with no prior infection developing an infection. Commonly known as a childhood infection, seroconversion in tropical countries occurs at a later age than in temperate countries, making chickenpox common in adolescents and adults in the former. VZV can also be transmitted to susceptible persons from patients with shingles. Studies suggest that the risk of viral transmission is considerably less from shingles than from chickenpox. The widespread vaccination of healthy children against chickenpox in the US has led to herd protection and extremely low levels of hospitalisation and mortality from chickenpox in children and adults.
Varicella may be more severe in pregnant women, particularly in the last trimester, with the potential for congenital varicella syndrome or foetal mortality. Maternal varicella that develops within 5 days before or 2 days after delivery is potentially most serious for the newborn resulting in congenital chickenpox infection. Maternal antibodies to VZV may not have been formed or crossed the placenta, and VZV may infect the baby before or after delivery. Vaccination of women before pregnancy is therefore recommended.
Table 25.1 Vaccines Registered in Malaysia

While pregnant women should not have the vaccine, a pregnancy registry for those inadvertently given the vaccine within three months or during pregnancy found no cases of increased birth defects. To date, the reported adverse events for chickenpox vaccine received by the National Pharmaceutical Regulatory Agency (NPRA) are chickenpox-like rashes occurring 7–23 days post vaccination and fever.
Table 25.2 High-Risk Groups in Malaysia

Implications for Healthcare Workers (HCWs)
Healthcare workers are at elevated risk for VZV exposure and transmission. All HCWs without evidence of immunity should receive two doses of chickenpox vaccine. Serologic testing post-vaccination is not routinely recommended due to the limited sensitivity of commercial assays.
Evidence for Effectiveness
Studies have demonstrated high immunogenicity in adults following two doses of the Oka strain vaccine. Seroconversion rates exceed 94% after the second dose. Real-world data indicate a significant decline in chickenpox incidence and complications following implementation of adult and childhood vaccination programmes.
References
- Varicella and herpes zoster vaccines (2016). WHO position paper, June 2014–Recommendations. Vaccine. 34(2):198-199.doi: 10.1016/j.vaccine.2014.07.068. PMID: 26723191.
- Gabutti, G., Bolognesi, N., Sandri, F., Florescu, C., & Stefanati, A. (2019). Varicella zoster virus vaccines: an update. ImmunoTargets and Therapy. 8, 15–28. https://doi.org/10.2147/ITT.S176383
- Anne A Gershon, Michael D Gershon, Eugene D Shapiro (2021). Live Attenuated Varicella Vaccine: Prevention of Varicella and of Zoster. Journal of Infectious Disease. S387–S397, https://doi.org/10.1093/infdis/jiaa573
- Centers for Disease Control and Prevention (2021). Epidemiology and Prevention of Vaccine-Preventable Diseases. Hall E., Wodi A.P., Hamborsky J., et al., eds. 14th ed. Washington, D.C. Public Health Foundation.